Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC

by Joy Lin
Share To

Taiwan’s Bora Pharmaceuticals and South Korea’s Celltrion Asia Pacific Pte, a subsidiary of Celltrion Group Inc, have announced a partnership to contract manufacture and bring to market a range of oral dosage form drugs (OSD) across the Asia-Pacific region. 

The oral drugs will be manufactured at Bora’s Zhunan site, which is one of the largest US FDA and MHRA-approved drug production plants in Taiwan. The manufactured products will be used to support Celltrion’s regulatory filings for approval in seven countries. 

This could include Celltrion’s oral infliximab, a tumor necrosis factor-alpha inhibitor for the treatment of inflammatory bowel disease (IBD). The company is currently advancing the formulation with UK-based Intract Pharma.  

Apart from manufacturing, Bora will also aid the commercialization of Celltrion’s products through its complex oral dosage form and total-solution services. 

“We are extremely excited about this new partnership with Celltrion. As a trusted global partner, we look forward to serving our customers with the best technology and quality resources and supporting our partners to expand into various markets around the world,” said Bobby Sheng, CEO and Chairman of Bora. 

Related article: Bora Pharmaceuticals Expands with Eden Biologics’ CDMO Purchase 

Bora Acquires TWi and Eden Biologics

As part of its five-year growth strategy, Bora has been on a buying spree for companies with manufacturing abilities. Last October, the CDMO completed the acquisition of a fellow Taiwan-based company, TWi Pharmaceutical, adding two production plants to boost formulation development, sterile ophthalmic, and niche manufacturing technologies. 

A few months earlier, Bora brought in Eden Biologics’ CDMO assets with an initial investment of $50 million and up to $100 million in a bid to rapidly scale a presence in biological macromolecules and cell and gene therapy markets. 

The latest acquisitions have brought Bora’s number of CGMP manufacturing facilities to seven across Taiwan and Canada. Besides OSD drugs, Bora also offers end-to-end services for non-sterile liquids, sterile and non-sterile ophthalmic, nasal sprays, and semi-solid pharmaceutical products. 

© All rights reserved. Collaborate with us:
Related Post
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
Japan’s Red Biotechnology and International Business Partnering Take Spotlight on BioJapan 2023
GeneOnline’s Weekly News Highlights: Oct 22-Oct 27
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top